Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Myelodysplastic Syndromes 1Leukemia, Myeloid, Acute 1

Interventions

Cytarabine 7Daunorubicin 5Azacitidine 5venetoclax 3Decitabine 3ivosidenib 2decitabine and cedazuridine drug combination 2cedazuridine 2Mitoxantrone 2Idarubicin 2Etoposide 2treosulfan 1tagraxofusp 1revumenib 1quizartinib 1olutasidenib 1glasdegib 1gilteritinib 1fludarabine 1etoposide phosphate 1enasidenib 1cc-486 1Midazolam 1Itraconazole 1Granulocyte Colony-Stimulating Factor 1Gemtuzumab 1Drug Therapy 1Cobicistat 1CPX-351 1Busulfan 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has announcements × Leukemia, Myeloid, Acute × olutasidenib × Clear all
NCT02719574 2025-06-26

Open-label Study of FT-2102 With or Without Azacitidine or Cytarabine in Patients With AML or MDS With an IDH1 Mutation

Novo Nordisk A/S

Phase 1/2 Completed
336 enrolled 48 charts 1 FDA
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡